FluoroPharma Medical, Inc. is a company seeking to develop breakthrough molecular imaging agents for the PET (positron emission tomography) type of 3D medical imaging of the human body to meet critical medical needs. The company is not involved with the … Continue reading →

Turning a good idea into a money making product can be a formidably expensive project, especially when dealing with medical substances to be introduced to the human body. FluoroPharma, developer of medical diagnostic imaging agents for use with PET (positron … Continue reading →

For many emerging companies, the ideal exit is a big-money major-corporate buyout, giving principals and investors a whopping return. Unfortunately, it’s not the most common outcome. Getting the right mix of technology, application, market demand, management, and financing is definitely … Continue reading →

When FluoroPharma CEO, Thijs Spoor, recently gave a presentation summarizing the rising importance in medical diagnostics of PET technology, and the associated radiopharmaceuticals such as those developed by FluoroPharma, it brought into focus a major gap between the promise of … Continue reading →

It’s almost impossible to overstate the significance of medical imaging in the development of modern medicine. The New England Journal of Medicine, considered the world’s oldest and single most influential general medical periodical, calls medical imaging one of the top … Continue reading →

FluoroPharma Medical, a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products, announced that its president and CEO, Thijs Spoor, will be presenting at Noble Financial Capital Markets’ Eight Annual Equity Conference. Mr. Spoor is scheduled … Continue reading →

In medicine, there’s no more important organ than the heart, the pump that circulates oxygen carrying blood throughout the body, keeping every cell alive. When circulation stops, so does life. The single biggest cause of death worldwide is heart disease, … Continue reading →

Fluoropharma Medical, developer of advanced medical diagnostic imaging products, sees an open-ended range of potential markets in its future, since many of the possibilities related to the advanced imaging technologies on which the company is focused have only begun to … Continue reading →

FluoroPharma Medical, a biopharmaceutical company providing proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels, announced that it has appointed Lawrence Atinsky to its Board of Directors. The appointment is effective January 3, 2012. Mr. … Continue reading →